LIDE
Shanghai LIDE Biotech is a premier preclinical oncology CRO dedicated to advancing translational medical research. Our core portfolio features classical CDX and over 2,200 Patient-Derived Xenograft (PDX) models across 40+ cancer types, including 188 with KRAS mutations. We stand apart with 200+ naturally drug-resistant models and proprietary 7-day in-vivo assays, MiniPDX and IO FIVE, alongside advanced 2D/3D in-vitro platforms. Founded in 2011, LIDE operates world-class, AAALAC-accredited SPF animal centers and BSL-2 laboratories. Our elite scientific team utilizes state-of-the-art equipment and the highest international standards to deliver high-fidelity data for global oncology discovery programs.
